RWJ 67657

Drug Profile

RWJ 67657

Alternative Names: RWJ-67657

Latest Information Update: 27 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class Antirheumatics; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV-1 infections; Rheumatoid arthritis

Most Recent Events

  • 16 Nov 2004 A preclinical study has been added to the Rheumatic Disease pharmacodynamics section
  • 09 Aug 2004 Data presented at the 15th International AIDS Conference (IAC-2004) have been added to the Viral Infections antimicrobial activity section
  • 24 Jun 2004 Data presented at the Annual European Congress of Rheumatology (EULAR-2004) have been added to the Rheumatic Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top